SCHEMBL501730

SCHEMBL501730

Cc1ccc(C([O])=O)c(C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 1/20 0.49
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 1/20 0.47
TP53 P04637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HSD11B1 P28845 1/20 0.46
MEN1 O00255 2/20 0.44
FLT1 P17948 1/20 0.44
FLT4 P35916 1/20 0.44
KDR P35968 1/20 0.44
CSNK2A1 P68400 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
TAS1R2 Q8TE23 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
CES2 O00748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31369141 0.83 LMNA (0.50) NFE2L2KMT2ASMN1; SMN2HTTTP53
SCHEMBL286054 0.83 LMNA (0.50) NFE2L2KMT2ASMN1; SMN2HTTTP53
SCHEMBL9420260 0.83 NFE2L2 (0.55) NFE2L2KMT2ASMN1; SMN2HTTTP53
SCHEMBL29381894 0.81 KMT2A (0.51) NFE2L2KMT2ASMN1; SMN2HTTTP53
SCHEMBL107259 0.81 CSNK2A1 (0.59) NFE2L2KMT2ASMN1; SMN2HTTTP53
SCHEMBL30679777 0.81 CSNK2A1 (0.59) NFE2L2KMT2ASMN1; SMN2HTTTP53
SCHEMBL96218 0.81 KMT2A (0.51) NFE2L2KMT2ASMN1; SMN2HTTTP53
SCHEMBL501733 0.81 MEN1 (0.55) KMT2ASMN1; SMN2HTTMEN1CSNK2A1
SCHEMBL10952578 0.79 ALDH1A1 (0.58) NFE2L2KMT2ASMN1; SMN2HTTNPC1
SCHEMBL6915656 0.79 CSNK2A1 (0.57) NFE2L2KMT2ASMN1; SMN2HTTHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345664-B2 Process for the preparation of (S)-Netarsudil,its salts and polymorphs Micro Labs Ltd. (IN) 2022-05-31 US claimed
US-20210094918-A1 PROCESS FOR THE PREPARATION OF (S)-NETARSUDIL,ITS SALTS AND POLYMORPHS Micro Labs Ltd. (IN) 2021-04-01 US claimed
WO-2021001713-A1 PROCESS FOR THE PREPARATION OF (S)-NETARSUDIL, ITS SALTS & POLYMORPHS MICRO LABS LIMITED (IN) 2021-01-07 WO claimed
US-5574016-A Peptide compound and a process for the preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-11-12 US claimed
US-4416879-A CEPHALOSPORINS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-11-22 US claimed
CN-117957265-A Process for producing dihydroxy compound and process for producing regenerated resin 三菱瓦斯化学株式会社 2024-04-30 CN disclosed
CN-117916325-A Thermoplastic resin composition, molded article, method for producing thermoplastic resin composition, and method for improving transmittance 三菱瓦斯化学株式会社 2024-04-19 CN disclosed
US-20230295373-A1 THERMOPLASTIC RESIN COMPOSITION FOR OPTICAL MATERIAL, MOLDED ARTICLE, COMPOUNDING AGENT, METHOD FOR PRODUCING THERMOPLASTIC RESIN COMPOSITION, AND METHOD FOR IMPROVING TRANSMISSIVITY MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2023-09-21 US disclosed
EP-4198092-A1 THERMOPLASTIC RESIN COMPOSITION FOR OPTICAL MATERIAL, MOLDED ARTICLE, COMPOUNDING AGENT, METHOD FOR PRODUCING THERMOPLASTIC RESIN COMPOSITION, AND METHOD FOR IMPROVING TRANSMISSIVITY MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2023-06-21 EP disclosed
CN-116096779-A Thermoplastic resin composition for optical material, molded article, compounding agent, method for producing thermoplastic resin composition, and method for improving transmittance 三菱瓦斯化学株式会社 2023-05-09 CN disclosed
WO-2023068290-A1 THERMOPLASTIC RESIN COMPOSITION, MOLDED ARTICLE, AND METHOD FOR PRODUCING AND METHOD FOR IMPROVING TRANSMITTANCE OF THERMOPLASTIC RESIN COMPOSITION 三菱瓦斯化学株式会社 2023-04-27 WO disclosed
US-11345664-B2 Process for the preparation of (S)-Netarsudil,its salts and polymorphs Micro Labs Ltd. (IN) 2022-05-31 US disclosed
US-5342935-A Antagonists of immunosuppressive macrolides MERCK & CO., INC. (US) 1994-08-30 US disclosed
EP-0608198-A1 Cyclic diphenylacetonenitriles as stabilisers CIBA-GEIGY AG (CH) 1994-07-27 EP disclosed
EP-0591102-A1 3-(2-Acyloxyethoxyphenyl)benzofuran-2-ones as stabilizers CIBA-GEIGY AG (CH) 1994-04-06 EP disclosed
EP-0589839-A1 3-(Dihydrobenzofuran-5-yl)benzofuran-2-ones as stabilizers CIBA-GEIGY AG (CH) 1994-03-30 EP disclosed
US-5190950-A Antagonists of immunosuppressive macrolides MERCK & CO., INC. (US) 1993-03-02 US disclosed
US-5155113-A Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-10-13 US disclosed
EP-0463690-A1 Antagonists of immunosuppressive macrolides MERCK & CO. INC. (US) 1992-01-02 EP disclosed
EP-0180188-A2 A composition for increasing the anti-cancer activity of an anti-cancer compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094918-A1 PROCESS FOR THE PREPARATION OF (S)-NETARSUDIL,ITS SALTS AND POLYMORPHS VKORC1L1, CYP3A4, REN NFE2L2 2259/4885KMT2A 3775/4885SMN1; SMN2 2773/4885
US-11345664-B2 Process for the preparation of (S)-Netarsudil,its salts and polymorphs VKORC1L1, CYP3A4, REN NFE2L2 2259/4885KMT2A 3775/4885SMN1; SMN2 2773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.